FBR & Co reaffirmed their outperform rating on shares of Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) in a report published on Tuesday morning. They currently have a $180.00 target price on the biopharmaceutical company’s stock.
A number of other analysts have also recently issued reports on the company. Leerink Swann reissued a buy rating on shares of Alnylam Pharmaceuticals in a research report on Monday. Morgan Stanley set a $93.00 price objective on Alnylam Pharmaceuticals and gave the company a buy rating in a research note on Tuesday, September 6th. Goldman Sachs Group Inc. reaffirmed a neutral rating and set a $65.00 price objective (up from $63.00) on shares of Alnylam Pharmaceuticals in a research note on Wednesday, August 10th. Zacks Investment Research raised Alnylam Pharmaceuticals from a sell rating to a buy rating and set a $85.00 price objective for the company in a research note on Tuesday, August 9th. Finally, Cowen and Company reaffirmed a buy rating and set a $150.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Sunday, August 7th. Three investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $110.79.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 69.94 on Tuesday. Alnylam Pharmaceuticals has a 52 week low of $49.96 and a 52 week high of $110.75. The firm’s market capitalization is $6.00 billion. The stock has a 50 day moving average price of $73.51 and a 200-day moving average price of $66.20.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.24) by $0.19. The firm earned $8.70 million during the quarter, compared to analysts’ expectations of $8.09 million. Alnylam Pharmaceuticals had a negative return on equity of 29.60% and a negative net margin of 1,204.91%. The business’s revenue was up .2% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.85) EPS. On average, analysts anticipate that Alnylam Pharmaceuticals will post ($4.64) EPS for the current year.
In other Alnylam Pharmaceuticals news, CEO John Maraganore sold 30,151 shares of the stock in a transaction on Wednesday, July 20th. The stock was sold at an average price of $64.69, for a total transaction of $1,950,468.19. Following the sale, the chief executive officer now owns 148,465 shares in the company, valued at approximately $9,604,200.85. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 4.00% of the company’s stock.
A number of large investors have recently made changes to their positions in ALNY. Wellington Management Group LLP boosted its stake in shares of Alnylam Pharmaceuticals by 12.1% in the first quarter. Wellington Management Group LLP now owns 11,945,607 shares of the biopharmaceutical company’s stock worth $749,826,000 after buying an additional 1,288,123 shares during the period. Vanguard Group Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 3.5% in the second quarter. Vanguard Group Inc. now owns 5,385,509 shares of the biopharmaceutical company’s stock worth $298,843,000 after buying an additional 182,614 shares during the period. Baillie Gifford & Co. boosted its stake in shares of Alnylam Pharmaceuticals by 0.3% in the second quarter. Baillie Gifford & Co. now owns 3,390,252 shares of the biopharmaceutical company’s stock worth $188,125,000 after buying an additional 10,317 shares during the period. Dodge & Cox bought a new stake in shares of Alnylam Pharmaceuticals during the second quarter worth approximately $139,650,000. Finally, State Street Corp boosted its stake in shares of Alnylam Pharmaceuticals by 13.4% in the second quarter. State Street Corp now owns 2,195,504 shares of the biopharmaceutical company’s stock worth $121,832,000 after buying an additional 258,984 shares during the period. Hedge funds and other institutional investors own 85.96% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.